View in EDS

A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.

Saved in:
Bibliographic Details
Title: A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
Authors: Heussler H; Centre for Clinical Trials in Rare Neurodevelopmental Disorders, Children's Health Queensland, Brisbane, Australia.; Centre for Child Health Research, University of Queensland, Brisbane, Australia., Cohen J; Fragile X Alliance Inc. and Genetic Clinics Australia, Melbourne, Australia., Silove N; The Children's Hospital at Westmead, Sydney, Australia., Tich N; Zynerba Pharmaceuticals, Devon, PA, 19333, USA. TichN@Zynerba.com., Bonn-Miller MO; Canopy Growth Corporation, Smith Falls, Ontario, V7A 0A8, Canada., Du W; Clinical Statistics Consulting, Blue Bell, PA, 19422, USA., O'Neill C; Zynerba Pharmaceuticals, Devon, PA, 19333, USA., Sebree T; Zynerba Pharmaceuticals, Devon, PA, 19333, USA.
Source: Journal of neurodevelopmental disorders [J Neurodev Disord] 2019 Aug 02; Vol. 11 (1), pp. 16. Date of Electronic Publication: 2019 Aug 02.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101483832 Publication Model: Electronic Cited Medium: Internet ISSN: 1866-1955 (Electronic) Linking ISSN: 18661947 NLM ISO Abbreviation: J Neurodev Disord Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 31370779
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Heussler+H%22">Heussler H</searchLink>; Centre for Clinical Trials in Rare Neurodevelopmental Disorders, Children's Health Queensland, Brisbane, Australia.; Centre for Child Health Research, University of Queensland, Brisbane, Australia.<br /><searchLink fieldCode="AU" term="%22Cohen+J%22">Cohen J</searchLink>; Fragile X Alliance Inc. and Genetic Clinics Australia, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Silove+N%22">Silove N</searchLink>; The Children's Hospital at Westmead, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Tich+N%22">Tich N</searchLink>; Zynerba Pharmaceuticals, Devon, PA, 19333, USA. TichN@Zynerba.com.<br /><searchLink fieldCode="AU" term="%22Bonn-Miller+MO%22">Bonn-Miller MO</searchLink>; Canopy Growth Corporation, Smith Falls, Ontario, V7A 0A8, Canada.<br /><searchLink fieldCode="AU" term="%22Du+W%22">Du W</searchLink>; Clinical Statistics Consulting, Blue Bell, PA, 19422, USA.<br /><searchLink fieldCode="AU" term="%22O'Neill+C%22">O'Neill C</searchLink>; Zynerba Pharmaceuticals, Devon, PA, 19333, USA.<br /><searchLink fieldCode="AU" term="%22Sebree+T%22">Sebree T</searchLink>; Zynerba Pharmaceuticals, Devon, PA, 19333, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101483832%22">Journal of neurodevelopmental disorders</searchLink> [J Neurodev Disord] 2019 Aug 02; Vol. 11 (1), pp. 16. <i>Date of Electronic Publication: </i>2019 Aug 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101483832 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1866-1955 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2218661947%22">18661947 </searchLink><i>NLM ISO Abbreviation: </i>J Neurodev Disord <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31370779
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s11689-019-9277-x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 16
    Titles:
      – TitleFull: A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Heussler H
      – PersonEntity:
          Name:
            NameFull: Cohen J
      – PersonEntity:
          Name:
            NameFull: Silove N
      – PersonEntity:
          Name:
            NameFull: Tich N
      – PersonEntity:
          Name:
            NameFull: Bonn-Miller MO
      – PersonEntity:
          Name:
            NameFull: Du W
      – PersonEntity:
          Name:
            NameFull: O'Neill C
      – PersonEntity:
          Name:
            NameFull: Sebree T
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 08
              Text: 2019 Aug 02
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-electronic
              Value: 1866-1955
          Numbering:
            – Type: volume
              Value: 11
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal of neurodevelopmental disorders
              Type: main
ResultId 1